Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer
Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma
FDA Grants Fast Track Designation to Amezalpat for Hepatocellular Carcinoma
Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront
2 Commerce Drive
Cranbury, NJ 08512